Dr. Wantanee Phuapradit has been confidently leading, directing, and making decisions on a large drug development portfolio in an entrepreneurial setting through all phases including early-stage product selection, product development, technology transfer, regulatory submission, FDA approval and commercialization. Leader of high-performing scientific and technical cross functional teams of pharmaceutical development scientists and other related CMC functions. Provides committed and inspiring leadership, stewardship and advocacy, striving for compound and manufacturing process knowledge development, continuous improvement, acceleration, risk assessment and mitigation, resource allocation and support. Ensures an effective Target Product Profile is in place which defines product characteristics and performance expectations to inform pharmaceutical development success.

Dr. Phuapradit has been serving as a scientific advisor and consultant in pharmaceutical R&D organizations. She previously served multiple R&D leadership roles with increasing responsibility including:

• Chief Scientific Officer at Tulex Pharmaceuticals
• Former Senior Vice President and Head of the Formulation Research and Development Group at Kashiv Pharma
• Former Senior Director of Barr/Teva
• 18 years with Hoffmann La Roche, including Senior Research Leader position

She holds a Ph.D. in Pharmaceutics from St. John’s University in New York City with over 30 years of experience in pharmaceutical oral dosage development, scale-up, technology transfer of generics, 505b2, and new chemical entities. Accolades include over 20 patents, 10 publications, and over 20 presentations/speaker events all specializing in pharmaceutical excellence.